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Quantification of pharmaceutical peptides using
selenium as an elemental detection label
Laura Hyrup Møller,a Charlotte Gabel-Jensen,a Henrik Franzyk,b
Jesper Søborg Bahnsen,a Stefan Stu¨rupa and Bente Gammelgaard*a
The aim of the present work was to demonstrate how selenium labelling of a synthetic cell-penetrating
peptide may be employed in evaluation of stability and quantitative estimation of cellular uptake by
inductively coupled plasma mass spectrometry (ICP-MS). Two analogues of the cell-penetrating peptide,
penetratin, were synthesized, one with selenomethionine (SeMet) added at the N-terminal of the peptide
(N-PenMSe) and the other with the internal methionine (Met) replaced with SeMet (i-PenMSe). The purity of
the synthesized peptides was 92% for N-PenMSe and 89% for i-PenMSe as determined by liquid
chromatography (LC)-ICP-MS. The selenium-labelled peptides were investigated by cell uptake studies in
HeLa WT cells. The stability of the peptides was monitored in water, cell medium and during cell uptake
studies. Total uptake of selenium was quantified by flow injection (FI)-ICP-MS. Speciation analysis of cell
samples by LC-ICP-MS showed mainly uptake of the intact peptides, while the amount of intact peptides
in cell lysates was semi-quantitatively determined. The selenium-containing penetratin analogues were to
some extent degraded in pure cell medium, while an extensive degradation was observed during cell
uptake studies. The major degradation products were determined by LC-electrospray ionization mass
spectrometry (ESI-MS). The labelling method in combination with FI-ICP-MS, LC-ICP-MS and LC-ESI-MS
techniques provided detailed information on the fate of penetratin in cellular uptake studies. Most
pharmaceutical peptides, including penetratin, are synthetic analogues of endogenous peptides, and
incorporation of selenium may improve the critical assessment of the native drug or drug delivery
candidate early in the drug development process.
Introduction
Peptides are involved in a large variety of physiological processes
and cell functions and several peptide drugs have already been
successfully applied for treatment of, for instance, certain cancer
forms and type 2 diabetes. The interest in exploiting peptides as
drug substances has increased rapidly during the last few
decades. Although the annual sale of peptide drugs is only a
few percent of the global drug market, it is increasing twice as
fast as the market for classical small molecules.1 In the period of
2000–2012, marketing approvals for 19 peptides were obtained
in USA, six of these were approved in 2012. A large number of
peptides are in the pipeline and several have reached the Phase
II and Phase III clinical trials. The therapeutic areas of the Phase
I and Phase II candidates are mainly metabolic diseases and
oncology, while the major indications for the Phase III candi-
dates are oncology and infectious diseases.2
Peptides often oﬀer high eﬃcacy, selectivity and specificity as
drug candidates, and as their degradation products are amino acids
and smaller peptides they are associated with low risk of systemic
toxicity. However, peptides exhibit low oral bioavailability owing to
their high propensity to enzymatic degradation in the gastro-
intestinal tract combined with a low intestinal barrier passage.3
Development of drug delivery systems is therefore an integrated
research area for improving the bioavailability of potential drug
candidates.4 Drug delivery by nanoparticles and development of cell
penetrating peptides (CPPs) are examples of such eﬀorts.5
In order to monitor the stability, pharmacokinetics and
metabolism of pharmaceutical peptides, development of sensi-
tive quantitative analytical methods for peptides is of great
importance. A challenge in monitoring the fate of peptides in
complex biological systems is to obtain adequate selectivity and
sensitivity.
Pharmaceutical peptides comprising 5–50 amino acids are
predominantly produced by solid-phase peptide synthesis
(SPPS). This opens up the possibility of introducing a label
for detection and thereby enhance analytical selectivity.3,6
Quantification of peptides has traditionally been performed by
liquid chromatography (LC) with detection by UV absorption7–9 or
a University of Copenhagen, Department of Pharmacy, Denmark.
E-mail: bente.gammelgaard@sund.ku.dk
b University of Copenhagen, Department of Drug Design and Pharmacology,
Denmark
Received 21st March 2014,





1640 | Metallomics, 2014, 6, 1639--1647 This journal is©The Royal Society of Chemistry 2014
fluorescence emission spectroscopy.10,11 However, UV detection
has limited sensitivity and specificity, whereas fluorescence detec-
tion demands either inherent fluorescent properties of the
biomolecule or labelling with a fluorophore. With development
of high-resolution mass spectrometry (MS), this technique is
increasingly applied in quantitative peptide analysis.12 Recently,
inductively coupled plasma mass spectrometry (ICP-MS) was
proposed as a complementary method to molecular MS for
quantification of peptides. The advantages of ICP-MS are low
detection limits, a wide dynamic range and in principle matrix-
independent sensitivity of different species of the heteroelements.
This opens up the opportunity for quantification by using a single
inorganic element standard in contrast to species-specific stan-
dards needed for molecular MS.13,14 However, detection of C, O
and N, the main constituents of biomolecules, is not possible by
ICP-MS due to use of an open plasma causing interferences from
the air. Fortunately, a wide range of proteins naturally contain
ICP-MS detectable heteroelements, e.g. S in methionine (Met) and
cysteine (Cys), Se in selenoproteins, P in phosphoproteins or I in
thyroid hormones. The occurrence of selenoproteins, phospho-
proteins and thyroid hormones is moderate in number, and
sulfur analysis is restricted due to low ionization efficiency and
spectral interferences in ICP-MS resulting in lower sensitivity.13 In
order to enhance sensitivity, several different ICP-MS sensitive
labels have been suggested, and these possibilities have been
reviewed by Prange and Pro¨frock,13 Kretschy et al.15 and Wang
et al.16 Two different approaches are generally pursued when
labelling biomolecules: pre-labelling and post-labelling. In pro-
teomics, post-labelling is often applied via labelled antibodies
targeting the biomolecule17 or through direct conjugation with
derivatizing agents.18 In the pre-labelling approach the biomole-
cule is labelled prior to its introduction into a biological system
and hence it remains detectable throughout the experiment. This
approach is mainly used when analyzing smaller biomolecules as
in the present work.
The ideal peptide labelling probe should enhance the sensi-
tivity and neither aﬀect the functionality of the peptide nor the
analytical properties. Incorporation of the label should be well
controlled, easy to handle and stoichiometrically unequivocal. All
these requirements are not readily achieved. Only a few studies on
elemental labelling for ICP-MS analysis of therapeutic peptides
have been reported, mainly involving chelating agents.15,19
Chelating agents typically consist of a lanthanide/metal chelating
moiety linked to a reactive group targeting a specific functional
group in the peptide, e.g. primary amines or thiols in cysteines.
Liu et al. addressed the importance of monitoring the labelling
procedure ensuring 1 : 1 labelling stoichiometry. They reported
that a mixture of labelled bradykinin with peptide : label ratios of
1 : 1 and 2 : 1 was obtained by use of a reactive moiety containing
two reactive groups, diethylenetriamine-N,N,N0,N00,N00-pentaacetic
dianhydride (DTPAA), selective for conjugation to primary
amines.20 In addition, labelling with DTPAA may result in diaster-
eomeric mixtures of the labelled peptides challenging the sub-
sequent analysis.21 Labelling reactions have been optimized to
avoid formation of diastereomers,22 however, consideration for
the possible presence of multiple labelling sites in the peptide is
important. Furthermore, subsequent separation of free label and
labelled peptide is necessary during pre-labelling.23 A few studies
have demonstrated labelling with indium by use of DOTA (1,4,7,10-
tetraazacyclododecane-N,N0,N00,N0 0 0-tetraacetic acid), introducing
the label during peptide synthesis, ensuring 1 : 1 labelling stoichio-
metry.24,25 The advantage of lanthanide or metal chelating agents
is considerably enhanced sensitivity of the biomolecule during
ICP-MS analysis, however, the relatively large chelating moiety will
aﬀect the peptide structure and thereby the physico-chemical
properties and potentially cell uptake, which is undesirable in
studies employing pre-labelled peptides.
In the present study, we introduce selenium as a label in
peptides by substitution of Met with the naturally occurring
selenium analogue, selenomethionine (SeMet) during peptide
synthesis. Selenium labelling constitutes an attractive non-
interfering method of probing biological systems, while ensuring
unambiguous labelling stoichiometry. Sulfur and selenium
belong to the group of chalcogens in the periodic table and thus
display similar chemical characteristics.26 Due to these compar-
able properties, it may be assumed that peptides incorporating
SeMet instead of Met will display similar biological eﬀects. This is
corroborated by the fact that SeMet may randomly be exchanged
with Met in humans as the body cannot distinguish between Met
and SeMet.27 Synthetic selenopeptides have been examined for a
wide range of applications, for instance, synthetic exchange of
disulfide bridges in peptides with diselenide or selenosulfo
bridges has been reported for a wide range of bioactive peptides
in order to improve stability.28 Lang et al. have proposed intro-
duction of SeMet as an improved target for thiophilic labelling
with iodoacetamide reagents as compared to Met, since selenium
is more nucleophilic as compared to sulfur.29 To the best of our
knowledge, selenium has not previously been introduced as a
synthetic label for detection in quantitative analysis.
The aim of the present work was to explore whether sele-
nium labelling of a synthetic cell-penetrating peptide may be
employed in evaluation of stability and quantitative cell uptake
by ICP-MS. Labelling with SeMet was demonstrated for the cell-
penetrating peptide (CPP) penetratin, consisting of 16 amino
acids including a Met residue, RQIKIWFQNRRMKWKK. The
peptide was originally derived from the Drosophila antenna-
pedia transcription protein, and this 16-residue sequence was
shown to be one of the minimal peptide sequences maintaining
cell-penetrating properties.30 In addition, penetratin is able
to deliver covalently conjugated drug cargoes through cell
membranes, thus oﬀering potential opportunities in the devel-
opment of new drug delivery systems.5,31 Two selenium-
containing analogues were investigated, one with SeMet added
at the N-terminal of the peptide (N-PenMSe) and the other with
the internal Met replaced with SeMet (i-PenMSe).
Experimental
Instrumentation
Inductively coupled plasma mass spectrometry. All ICP-MS
measurements were performed on a PE Sciex ELAN 6000
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Inductively Coupled Plasma Mass Spectrometer (ICP-MS)
(Perkin Elmer, Norwalk, CT, USA) equipped with a MicroMist
glass nebulizer (AHF, Lab Support Hillerød, Denmark) and a
PC3 cyclonic spray chamber (Elemental Scientific Inc., Omaha.
NE, USA) operated at 4 1C. The sampler and skimmer cones
were made of platinum. The nebulizer gas flow, lens voltage
and ICP RF power were optimized daily using a solution of
100 mg Se per liter in mobile phase. The data acquisition
settings for flow injection – dwell time, 50 ms; sweeps per
reading, 1; and readings per replicate – were varied according to
the number of samples. For speciation analysis, a desolvation
system (Aridus II, CETAC Technologies) with a 200 mL min1
nebulizer was applied in order to remove the organic solvent
from the eluent prior to introduction into the ICP-MS. Desolva-
tion system settings: spray chamber temperature 110 1C;
desolvator temperature 160 1C; sweep gas flow 7 mL min1;
and nitrogen gas flow 6 mL min1. ICP-MS nebulizer gas flow
was 0.9 mL min1. Lens voltage and ICP RF power were
optimized regularly through the desolvation system on a
solution of i-PenMSe containing 10 mg of Se per liter in mobile
phase (50% methanol). Data acquisition settings for speciation
analysis: dwell time 200 ms; sweeps per reading 1; and readings
per replicate 1325. 77Se+, 78Se+ and 82Se+ isotopes were moni-
tored; 82Se+ was used for quantitative determination.
Molecular mass spectrometry. All MS measurements were
performed on a Q Exactive Orbitrap mass spectrometer
(Thermo Scientific) with 250 1C heated electrospray ionization.
The sheath gas was set to 30 arbitrary units; auxiliary gas to 10
arbitrary units; capillary temperature to 350 1C; and spray
voltage to 3300 V. The MS was run in full scan positive mode.
The scan range was 300–3000m/z, with a lock mass of 445.120m/z,
and themass accuracy was below 1 ppm. The instrument wasmass
calibrated prior to analysis.
Reagents
Rink amide resin, coupling reagents and amino acid building
blocks for solid-phase peptide synthesis as well as supplemen-
tary solvents and chemicals were acquired from Iris Biotech
(Marktredwitz, Germany). L-Selenomethionine (SeMet) was
obtained from TCI Europe. For mobile phases, glacial acetic
acid, trifluoroacetic acid (TFA) and methanol were obtained
from BDH Prolabo (France).
Procedures
Peptide synthesis and labelling. All peptides were synthe-
sized by Fmoc-based solid-phase peptide synthesis (SPPS) using
a microwave-assisted automated CEM Liberty synthesizer
(CEM, Matthews, NC, US). H-SeMet-OH was N-protected with
N-(9-fluorenylmethoxycarbonyloxy)succinimide (Fmoc-OSU) to
give Fmoc-SeMet-OH; 1H NMR (600 MHz, dimethylsulfoxide-
d6): d 12.66 (1H, –COOH), 7.89 (2H, d, J = 7.5 Hz, Fmoc Ar–H),
7.72 (1H, d, J = 7.5 Hz, Fmoc Ar–H), 7.72 (1H, d, J = 7.5 Hz, Fmoc
Ar–H), 7.67 (1H, d, J = 8.2 Hz, –OCONH–), 7.42 (2H, t, J = 7.5 Hz,
Fmoc Ar–H), 7.33 (2H, br t, J = 7. 5 Hz, Fmoc Ar–H), 4.33–4.27
(2H, m, Fmoc –CH2–), 4.23 (1H, br t, J = 7.1 Hz, Fmoc –CH–),
4.09 (1H, m, H-a), 2.58 (1H, ddd, J = 12.4, 8.7 and 5.1 Hz, HA-b),
2.51 (1H, obsc. by solvent peak, HB-b), 2.04–1.93 (2H, m, H-g),
1.94 (3H, s, –CH3).
13C NMR (150 MHz; dimethylsulfoxide-d6):
d 173.58, 156.18, 143.84, 143.77, 140.73, 140.72, 127.64 (2C),
127.06 (2C), 125.26, 125.24, 120.12, 120.10, 65.56, 53.61, 46.67,
31.39, 20.96, 3.46. N-terminal labelling of penetratin with SeMet
was performed using Fmoc-SeMet-OH (2.5 eq.), benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP;
2.5 eq.) and N,N-diisopropylethylamine (DIPEA; 5 eq.) in DMF
at room temperature for 3 h in a teflon reactor (10 mL) equipped
with a polypropylene filter. Incorporation of SeMet into i-PenMSe
was performed during automated peptide synthesis. Peptides
were purified by preparative HPLC (Luna C18(2) column, 5 mm,
250  21 mm; Phenomenex) with UV detection at 280 nm.
A linear gradient of 0–35% eluent B (H2O :MeCN 95 : 5 with
0.1% TFA) in eluent A (H2O :MeCN 5 : 95 with 0.1% TFA) within
20 min was applied. The flow rate was 20 mL min1.
Cell culture
The human cervical cancer cell line HeLa WT was obtained
from American Type Culture Collection (ATCC) and maintained
in Eagle’s minimal essential medium (EMEM) supplemented
with penicillin (100 U mL1), streptomycin (100 mg mL1),
L-glutamine (2 mM), non-essential amino acids (0.1 mM),
sodium pyruvate (1 mM) and 10% fetal bovine albumin (FBS)
(Fischer Scientific, Slangerup, Denmark). The cells were grown
in an atmosphere of 5% CO2 at 37 1C to 80% confluence and
then sub-cultured at a ratio of approximately 1 : 5 twice a week.
Cells, 7.6  104, were seeded onto 24-well plates (Fischer
Scientific, Slangerup, Denmark).
Cell uptake studies
Experiments were performed 22–24 h after seeding of the HeLa
WT cells; by then, a sub-confluent monolayer (80–90% conflu-
ence) was achieved. Peptide solutions (10 mM) in Hanks
Balanced Salt Solution (HBSS; Gibco, Paisley, UK) supplemented
with 10 mM 4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid
(HEPES, SigmaUltra) were prepared immediately prior to use in
cell uptake studies from aqueous 200 mM peptide stock solutions
prepared within 2 weeks from the uptake experiment and stored
at 4 1C. The uptake study was initiated by washing the cells once
with 37 1C phosphate buffered saline (PBS, Sigma), and subse-
quent addition of 400 mL of peptide solution. The cells were then
incubated with peptide solution for 2 h on an orbital shaker
(90 rpm) at 37 1C. After exactly 2 h, medium was collected and
immediately acidified with acetic acid to a final concentration of
2%. The cell uptake was terminated by washing the cells four
times with ice-cold PBS, and then the cells were lysed by addition
of 100 mL of 0.1% Triton-X 100 in 2% acetic acid and kept on ice
for 10 min. The lysis mixture was transferred into low-binding
Eppendorf tubes (Alpha Laboratories), centrifuged at 25000 g
and the supernatant was collected for analysis. All samples were
stored at 18 1C until analysis.
Determination of total selenium by flow injection analysis
Total selenium was determined by flow injection analysis (FI)
using an aqueous carrier fluid of 0.02% trifluoroacetic acid (TFA),
Metallomics Paper
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0.1% acetic acid and 5% methanol. The flow rate was
200 mL min1 and the injection volume was 10 mL. Quantifica-
tion was performed by single standard calibration based on
peak areas of a 50 mg L1 solution of certified selenium
element standard (Se concentration of 1010 mg L1, PlasmaCAL,
SCP Science, Canada).
LC-ICP-MS (Aridus)
For LC-ICP-MS analysis, an Agilent 1100 series HPLC system
equipped with a degasser, a quaternary pump, an autosampler
and a column oven was used. The column was an Aeris
PEPTIDE XB-C18, 3.6 mm, 100  2.1 mm ID column protected
by a C18-Peptide SecurityGuard ULTRA cartridge (Phenomenex,
SupWare, Denmark). A linear gradient of 20–80% methanol,
(with 0.1% acetic acid and 0.05% TFA added) within 10 min was
applied with a flow rate of 200 mL min1, a column temperature
of 60 1C, and an injection volume of 5 mL. Semiquantitative
peptide uptake was determined by use of a single standard
solution of 2.4 mM i-PenMSe standardized for total selenium
content with a certified selenium element standard (Plasma-
CAL, SCP Science, Canada), concentration of 1010 mg L1 of Se.
LC-ESI-MS
UHPLC-ESI-MS analysis was performed on a Dionex Ultimate 3000
UHPLC (Thermo Scientific) equipped with a degasser, a quaternary
pump, an autosampler, a thermostated column compartment and a
diode array detector (DAD) and hyphenated to a Q Exactive Orbitrap
mass spectrometer. The column and mobile phase described for
LC-ICP-MS were applied for this system as well. However, the linear
gradient was shortened to 20–62% methanol (with 0.1% acetic acid
and 0.05% TFA added) within 7 min to reduce time of analysis.
MS data were collected between 2.5 and 10 min.
Results and discussion
Peptide synthesis
The obvious approach for labelling a peptide with selenium
would be to substitute a sulfur-containing amino acid with its
selenium analogue, i.e. selenocysteine (SeCys) or selenomethio-
nine (SeMet). Cysteine is usually avoided in peptide synthesis
because of high redox potentials and thereby low stability.
Selenoamino acids are generally more readily oxidized during
synthesis and purification compared to the sulfur analogues;
with the reactivity of SeCys exceeding that of SeMet.26 Thus,
SeMet was chosen for selenium labelling in the present study.
Exchange of Met in penetratin with other neutral amino acids,
leucine (Leu) or alanine (Ala), has been reported in the litera-
ture without a significant change in cell uptake in HeLa WT
cells and HaCAT cells respectively.32,33 Hence, exchange of Met
appears to be a convenient labelling site in penetratin.
Synthesis was carried out by employing microwave (MW)-
assisted automated solid-phase peptide synthesis (SPPS). In order
to test whether it was possible to introduce SeMet into the peptide
sequence with a reasonable yield and purity, a penetratin analogue
with SeMet added at the N-terminal (N-PenMSe) was initially
synthesized (sequence shown in Table 1). As a standard C - N
SPPS strategy was applied, the peptide was conveniently modified
by introduction of SeMet at the N-terminal subsequently to
MW-assisted automatic synthesis. Thereby, minimum exposure
of SeMet to reagents was ensured, and thus the risk of SeMet
oxidation was minimized. Also, it was intended to avoid MW
irradiation in this initial labelling experiment as it might not be
compatible with SeMet. Furthermore, N-terminal labelling of
penetratin has been widely used for introduction of fluorescent
dyes and covalent attachment of drug cargoes.34–36 Synthesis and
purification of N-PenMSe was accomplished, and purity of the
resulting selenopeptide was determined by LC-ICP-MS to be 92%
as illustrated in Fig. 1. It appears from the figure that an impurity,
eluting immediately before the desired peptide, was present. By
LC-ESI-MS, a signal was observed atm/z 606.831, corresponding to
the [M + 4H]4+ ion of a peptide with mass 2423.293 confirming
N-PenMSe (2423.290 Da) as the primary product (DM r 1 ppm).
A signal from the impurity was seen at m/z 606.326 corresponding
Table 1 Synthetic Se-containing penetratin analogues (i-PenMSe: internal
SeMet incorporated. N-PenMSe: SeMet added at the N-terminal)
Abbreviation Sequence Mmonoisotopic Maverage
i-PenMSe RQIKIWFQNRR(MSe)KWKK-NH2 2292.250 2292.638
N-PenMSe MSe-RQIKIWFQNRRMKWKK-NH2 2423.290 2423.834
Fig. 1 LC-ICP-MS chromatograms of i-PenMSe and N-PenMSe in water
and HBSS medium. The amount of the intact peptide determined as the
percentage of total selenium in the chromatogram: i-PenMSe in water:
89% and i-PenMSe in HBSS: 81%; N-PenMSe in water: 92% and N-PenMSe in
HBSS: 86%.
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to the [M + 4H]4+ ion representing a mass of 2421.273 Da (DMr
1 ppm) which is 2.020 Da less than that of N-PenMSe. A difference
of 2.020 Da might arise from loss of two hydrogen atoms
(2.016 Da) due to cyclization or formation of a double bond.
Introduction of SeMet within the peptide sequence by
exchange of Met was then pursued. By fully automated
MW-assisted SPPS, SeMet was incorporated at the original
position of Met into penetratin i-PenMSe, the sequence is
shown in (Table 1). Purity of the synthesized peptide was
determined by LC-ICP-MS to be 89%. LC-ESI-MS revealed a
signal at m/z 1147.132 corresponding to the [M + 2H]2+ ion of
the peptide, confirming the identity of i-PenMSe (2292.250 Da)
with a mass of 2292.248 Da (DM r 1 ppm) as the primary
product. The [M + 2H]2+ ion originating from the impurity
was observed at m/z 1155.131 corresponding to a mass of
2308.246 Da (DM r 1 ppm). The mass increase of 15.998 Da
indicated the presence of an additional oxygen atom (15.995 Da)
that may arise from oxidation of the peptide, most likely in the
SeMet residue. Oxidation of SeMet may have occurred during
synthesis due to the exposure to oxygen at elevated temperatures
in the synthesizer or during the purification process.
As only the oxidized impurity was identified for i-PenMSe,
mild synthesis conditions appear to be important in order to
avoid oxidation of SeMet. Furthermore, a slightly higher peptide
purity (92%) was obtained for N-PenMSe as compared to
i-PenMSe (89%). The purity of i-PenMSe might be improved in
future by manual synthesis of the peptide or by using lower
temperatures during coupling and deprotection steps. However,
manual peptide synthesis is considerably more time-consuming,
favoring automated synthesis. Improving the preparative HPLC
methodmight also result in increased purity of the final product.
The stability of i-PenMSe in water was monitored by LC-ICP-MS
during a two-month storage period. The ratio between the intact
peptide and the impurity remained constant throughout the
period (data not shown) confirming that the SeMet-labelled
peptide was stable in aqueous solution. By dilution of the
selenopeptides in HBSS medium, a decrease of the intact peptide
was immediately observed in LC-ICP-MS chromatograms (Fig. 1).
The mechanism behind this increased degradation is not clar-
ified, but may be due to the higher ionic strength of the HBSS
medium. The content of intact i-PenMSe decreased from 89% to
81%, while the content of intact N-PenMSe decreased from 92% to
86%. Only degradation to the formerly identified impurities was
observed, thus no oxidation of N-PenMSe was seen, whereas the
presence of an oxidation product of i-PenMSe increased. This
indicated that oxidation may be dependent on the position of
SeMet in the peptide sequence.
The stability of fluorescently labelled penetratin has been
investigated in a number of studies, as the translocation of the
peptide and its function as a drug carrier may be dependent on the
stability. Tre´hin and colleagues have shown considerable degrada-
tion of carboxyfluorescein-labelled penetratin (CF-penetratin) in
HBSS after 21 days of incubation, since only 76% of the intact
peptide remained.10 In PBS supplemented with 1 g L1 D-glucose,
CF-penetratin was shown to be stable for only 1 h.37 Thus,
instability is also observed for the native Met-based penetratin.
Cell uptake of selenopeptides
Determination of total selenium by FI-ICP-MS. To test
whether the synthesized selenium analogues of penetratin were
able to penetrate the cell membrane, a two-hour uptake study
in HeLa WT cells was conducted. Several studies have shown
translocation of penetratin into eukaryotic cells with the HeLa
WT cell line being one of the most frequently used cell lines.38
The total uptake of selenium from the peptides was deter-
mined by flow injection ICP-MS (FI-ICP-MS), (Table 2). SeMet was
included as a positive control of the cell uptake experiment setup,
as extensive cell uptake of SeMet has formerly been reported in
e.g. the Caco-2 cell line.39 Considerable amounts of i-PenMSe and
N-PenMSe were taken up by the cells, 17.4 2.2 pmol per 104 cells
of i-PenMSe and 25.4  2.9 pmol per 104 cells of N-PenMSe,
respectively. However, the selenium uptake from the peptides
was not as pronounced as from SeMet, 49.6  3.3 pmol per 104
cells. Blank lysates contained no selenium.
The cellular uptake of penetratin has been studied by several
groups in a variety of diﬀerent human cell lines. The majority of
these studies are based on fluorophore-labelled penetratin.
Determination of CF-penetratin uptake in four diﬀerent human
carcinoma cell lines by total fluorescence spectrophotometry
showed very diﬀerent degrees of peptide internalization
depending on the cell line.40,41 Lindgren and colleagues
reported 14% uptake of total fluorescence of 2-aminobenzoic
acid (Abz)-labelled penetratin in Caco-2 cells after 30 min
incubation with 10 mM peptide.34 Sarko et al. investigated the
cellular uptake of 111In-DOTA-labelled penetratin in six diﬀerent
human carcinoma cell lines, where the uptake was determined
using a g-counter. Upon incubation for 30 min with cells, the
amount of internalized radioactive label varied remarkably
between diﬀerent cell lines.25 As HeLa WT cells were not among
the investigated cell lines, these data are not directly comparable
to those obtained in the present work. Bahnsen et al. reported a
semi-quantitative uptake of CF-labelled penetratin analogues in
HeLa WT cells via determination by flowcytometry.32 However,
the results were presented as relative to CF-penetratin uptake
and they are thus not comparable to those of the present work.
Semi-quantitative determination of peptide uptake in HeLa
WT cells by LC-ICP-MS. FI-ICP-MS revealed a similar uptake of
selenium for i-PenMSe and N-PenMSe. Speciation analysis of the
lysates by reversed-phase (RP) LC-ICP-MS allowed estimation of
whether penetratin was taken up by HeLa WT cells as the intact
peptide or as degradation products. The amounts of peptide are
Table 2 Uptake in HeLa WT cells incubated for two hours with 10 mM of
i-PenMSe, N-PenMSe and SeMet. Total selenium in cell lysates was deter-
mined by FI-ICP-MS, results obtained from one passage, three indepen-
dent wells. Uptake of the intact peptide determined by LC-ICP-MS, results
obtained from one lysate
Start Se Total Se Intact peptide
pmol per 104 cells pmol per 104 cells pmol per 104 cells
i-PenMSe 505 17.4  2.2 16.1
N-PenMSe 484 25.4  2.9 18.4
SeMet 508 49.6  3.3 —
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shown in Table 2. Hyphenation of RP gradient systems to
ICP-MS is challenging, as the hot plasma in the ICP-MS will
extinguish when exposed to high concentrations of organic
solvent. This could be overcome by the use of narrow bore
columns decreasing the flow rate considerably. However the
use of high contents of MeOH may result in ICP-MS signal
drift.24 In this study, the organic solvent from the mobile phase
was removed by use of a membrane desolvation system. Chroma-
tograms of cell lysates (Fig. 2) revealed that the main component
passing the cell barrier in the case of both i-PenMSe and N-PenMSe
was the intact peptide. This was confirmed by LC-ESI-MS ([M +
2H]2+ m/z 1147.127, mass 2292.239, DMo 5 ppm and [M + 3H]3+
m/z 808.771, mass 2423.280, DM o 5 ppm, respectively). Thus
16.1 pmol per 104 cells of i-PenMSe and 18.4 pmol per 104 cells of
N-PenMSe were observed in the respective HeLa WT cell lysates
(Table 2). It is not possible from the present data to clarify if the
minor amount of degradation products observed in the lysates
entered the cells as such or were produced in the cells during
uptake studies. Otherwise they may have been formed during the
cell lysis upon adding a mixture of 0.1% triton X and 2%
CH3COOH. Very few studies have reported on speciation of cell
lysates. Holm et al. investigated the intracellular degradation of
CF-penetratin in yeast cells by RP-LC-fluorescence detection (FLD)
after one hour of incubation. They showed that a high total uptake
of the fluorophore was accompanied by extensive intracellular
degradation of the peptide.11 A similar pattern was reported by
Palm et al. for CF-penetratin uptake in non-mammalian cells
upon incubation for one hour.42 These results are in contrast to
the results of the present study. The percentage of intact peptides
observed in HeLa WT cell lysates was 73% and 76% for i-PenMSe
and N-PenMSe, respectively.
FI-ICP-MS and LC-ICP-MS of HeLa WT cell lysates demon-
strated that cellular uptake of i-PenMSe and N-PenMSe mainly
represented internalization of intact peptides. A direct compar-
ison of these results to the existing literature was not possible,
as diﬀerent cell models and labels were applied.
Degradation of selenopeptides during cell uptake studies.
Degradation of CF-penetratin has been reported to be a critical
determinant for cellular uptake of penetratin.37 In order to fully
exploit the drug delivery potential of penetratin, consistent
evaluation of cellular uptake and stability is critical. Thus,
degradation of the two synthetic selenopeptides, during incu-
bation with HeLa WT cells in HBSS cell medium for two hours,
was investigated. LC-ICP-MS analysis of samples from the HBSS
medium revealed considerable additional degradation of the
selenopeptides upon exposure to cells as compared to results
obtained in cell-free HBSS. This is shown in Fig. 3. It appears
that several new species appeared after exposure to cells in
medium as compared to the cell-free medium in Fig. 1. The
amount of the intact peptide present decreased for i-PenMSe
from 81% to 55%, while for N-PenMSe decreased from 86% to
61%. The enhanced degradation during exposure to HeLa WT
cells indicated that the degradation was primarily proteolytic
rather than chemical. Proteolytic degradation of CF-penetratin
when exposed to various cell lines has previously been corre-
lated to cell line-dependent variations in stability.10,34
In order to investigate the mode of degradation further, the
samples from the HBSS medium from uptake studies were
analyzed by LC-ESI-MS. Degradation products of i-PenMSe and
N-PenMSe were identified via their m/z values, and sequences
corresponding to these masses are suggested in Table 3. The
main compound observed for both i-PenMSe and N-PenMSe was
the intact peptide (Fig. 3, peak a). Similar cleavage sites were
observed for i-PenMSe and N-PenMSe as illustrated in Fig. 4.
Previous unpublished studies on penetratin stability by UPLC-
QTOF identified cleavage sites in native penetratin when
exposed to human and rat gastrointestinal fluid that corre-
spond to those observed for selenium-labelled penetratin ana-
logues in the present study.43 Cleavage at the C-terminal site of
arginine (R) and lysine (K) was confirmed to be caused by
trypsin whereas cleavage at the C-terminal site of phenylalanine
(F) was caused by chymotrypsin.43 Thus, the degradation
products c, d and e shown in Fig. 3 may be due to the presence
of trypsin while product f may be a result of chymotrypsin. The
composition of enzymes produced by HeLa cells is not
reported, but some proteolytic activity is expected, which may
include trypsin and chymotrypsin.
The degradation products identified from i-PenMSe and
N-PenMSe are listed in Table 3 and diﬀered in the presence of
selenium. In extracted ion chromatograms (EIC) of the LC-ESI-MS
analysis, dissimilarities were at first observed by just a minor
diﬀerence in the retention time of the peaks in the chromatograms
(Fig. 3). Comparison to the LC-ICP-MS chromatograms revealed
Fig. 2 LC-ICP-MS chromatograms of cell lysates from HeLa WT cells
incubated with 10 mM selenopeptide for 2 h.
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that the diﬀerence was due to the selenium labelling site. For
instance, peak f was present in the LC-ICP-MS chromatogram of
N-PenMSe in medium, but not in that of i-PenMSe in medium,
whereas the peak appeared in both LC-ESI-MS EICs. Zooming in
on the isotope patterns of the LC-ESI-MS peaks revealed a char-
acteristic pattern for compounds containing selenium which was
easily distinguished from a carbon pattern, exemplified for peak f
in Fig. 5. The short peptide RQIKIWF from i-PenMSe exhibited the
common peptide carbon pattern (12C, 98.90%; 13C, 1.10%). The
selenium-containing degradation product from N-PenMSe, MSeR-
QIKIWF, displayed a combined pattern of carbon and selenium
(76Se, 9.0%; 77Se, 7.6%; 78Se, 23.6%; 80Se, 49.7%; 82Se, 9.2%).
Hence, the characteristic isotope pattern of selenium demon-
strates that selenium is also a useful molecular MS label.
Thus, diﬀerences between selenium-containing degradation
products obtained from i-PenMSe and N-PenMSe, respectively,
were revealed by LC-ICP-MS (chromatograms in Fig. 3) as only
selenium-containing compounds were present. In general,
Fig. 3 Chromatograms of samples of Se-peptides in HBSS medium detected by ESI-MS and ICP-MS. MS chromatograms are extracted ion
chromatograms (EIC) (i-PenMSe m/z: [M + 2H]2+ 495.798; [M + 3H]3+ 515.637; [M + 2H]2+ 694.899; [M + 3H]3+ 722.721; [M + 3H]3+ 765.092; [M +
3H]3+ 770.425. N-PenMSe m/z: [M + 3H]3+ 523.264; [M + 3H]3+ 573.997; [M + 3H]3+ 575.998; [M + 2H]2+ 585.290; [M + 3H]3+ 697.409; [M + 3H]3+
766.400; [M + 3H]3+ 808.100; [M + 3H]3+ 808.774). Annotation of the peaks corresponds to peptide sequences presented in Table 3.
Table 3 Sequences and masses of identified degradation products in medium samples from cell uptake experiments of i-PenMSe and N-PenMSe
determined by LC-ESI-MS, mass accuracy r 1 ppm. Sequences annotated in conformity to chromatograms are shown in Fig. 3
i-PenMSe (1) Mmonoisotopic N-PenM
Se (2) Mmonoisotopic
a RQIKIWFQNRRMSeKWKK-NH2 2292.250 M
SeRQIKIWFQNRRKWKK-NH2 2423.290
b Oxidized i-PenMSe 2308.245 — —
c RQIKIWFQNRR-OH 1543.885 MSeRQIKIWFQNRR-OH 1722.870
d RQIKIWFQNR-OH 1387.784 MSeRQIKIWFQNR-OH 1566.769
e RQIKIWFQNRRMSeKWK-OH 2165.139 MSeRQIKIWFQNRRKWK-OH 2296.17
f RQIKIWF-OH 989.581 MSeRQIKIWF-OH 1168.566
g — — N-PenMSe – 2 Da 2421.275
h — — QIKIWFQNRRKWKK-NH2 2088.204
Fig. 4 Cleavage sites of i-PenMSe and N-PenMSe after 2 h of incubation
at 37 1C with HeLa WT-cells. Annotation corresponds to peaks in chro-
matograms in Fig. 3.
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amino acids and short polar peptides eluted in the beginning of
the LC-ICP-MS chromatograms, while larger fragments and oxida-
tion products appeared around the intact peptide. In N-PenMSe,
SeMet was added at the N-terminal, and was thus retained inmost
of the cleaved peptides resulting in larger selenium-containing
degradation products. By contrast, SeMet was incorporated
towards the highly positively charged C-terminal in i-PenMSe,
and therefore SeMet was predominantly cleaved oﬀ the parent
peptide as very polar smaller Se-containing peptides eluting in the
beginning of the chromatogram. Thus, the position of the label in
the peptide sequence must be considered carefully in develop-
ment and optimization of the LC methods. However, these results
demonstrated that selenium labelling of penetratin indeed may
be used as a readily detectable probe in evaluation of peptide
degradation in various matrices by LC-ICP-MS and LC-ESI-MS.
The possibility of specific detection of selenium oﬀered by the
ICP-MS technique implies that degradation in even more complex
sample matrices may be analyzed.
Analytical figures of merit
Total selenium uptake in HeLa cells was successfully quantified
by FI-ICP-MS while uptake of the intact peptide was semi-
quantitatively determined by LC-ICP-MS, exploiting the high
selectivity and robustness of the ICP ionization. The limit of
detection (LOD) of FI-ICP-MS was estimated to be 6.0 ng SemL1
(0.76 nmol Se injected) as 3s of the peak area of 2.4 mM i-PenMSe.
FI-ICP-MS precision of three repeated injections of 2.4 mM
i-PenMSe was 1.0% relative standard deviation (RSD). The LOD
for the LC-ICP-MS method was 6.5 ng Se mL1 (0.41 nmol Se on
column) estimated as 3s of the peak area of 2.4 mM i-PenMSe.
The column recovery was 101.5  1.1% (n = 3) and 101.9  0.3%
(n = 2) for i-PenMSe and N-PenMSe respectively. The precision of
three repeated injections of 2.4 mM i-PenMSe was 1.3% RSD.
The LOD for the FI-ICP-MS method in this study was higher
than what has previously been reported for low molecular sele-
nium compounds.39 Peptides are known to exhibit unspecific
adsorption onto diﬀerent materials, e.g. glass, metal and plastic.7
Adsorption onto vials, injection needle or tubing might explain
the increased LOD. The flow injection method was thoroughly
optimized to avoid unspecific adsorption by acidification and the
increase of the peptide concentration in samples. However,
adsorption might still contribute to increased deviation between
injections, resulting in a higher LOD for peptides as compared to
smaller selenium compounds. Furthermore, the low-abundant
selenium isotope 82Se (9.2%) was measured in the present work,
due to the polyatomic interference of 40Ar2 of the most abundant
isotope 80Se (49.7%) using the ELAN 6000 quadrupole instrument.
Suﬃcient sensitivity was achieved by ELAN 6000 for the measure-
ments of the present study. However, detection limits may be
reduced by application of improved ICP-MS instrumentation, e.g.
by applying a dynamic reaction cell (DRC) instrument.44
Conclusion
In this study, selenium incorporated as SeMet was demon-
strated to be a useful label for quantification of pharmaceuti-
cally relevant peptides exemplified by the cell-penetrating
peptide, penetratin. Selenium was readily introduced during
solid-phase peptide synthesis, however, the stability of SeMet at
higher temperatures must be considered. The introduction of
the non-toxic SeMet label is considered to have a minimal eﬀect
on the biological activity of the peptide. Selenium labelling thus
oﬀers minimal disturbance of the native structure of the
peptide of interest as compared to labelling with fluorophores
or metal-chelating agents. The labelling technique and a
combination of FI-ICP-MS, LC-ICP-MS and LC-ESI-MS techni-
ques provided detailed information on the fate of penetratin in
cell uptake studies. In addition to qualitative information on
degradation products obtainable from LC-ESI-MS, LC-ICP-MS
allowed for quantification of the peptide. Most therapeutic
peptides are synthetic analogues of endogenous peptides, and
incorporation of selenium allows for improved critical assess-
ment of the native drug or drug delivery candidate early in the
drug development process.
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